- Market Capitalization, $K 523,684
- Shares Outstanding, K 73,448
- Annual Sales, $ 143,010 K
- Annual Income, $ -400,420 K
- 60-Month Beta 3.12
- Price/Sales 2.77
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-0.68 (-9.03%)since 02/28/20
| || |
-4.30 (-38.57%)since 12/27/19
| || |
-17.97 (-72.40%)since 03/29/19
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis Oncology (CLVS) closed the most recent trading day at $4.50, moving +0.45% from the previous trading session.
Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $4.40 to a high of $5.64. Yesterday, the shares fell 7.3%, which took the trading range below the 3-day low of $4.91...
Opioid drugs are and have been a God-send for many patients whose severe, excruciating pain had no other drug or device to allow them to escape from its throes. But we all know that the other side of that...
Clovis Oncology (CLVS) closed the most recent trading day at $6.17, moving -1.59% from the previous trading session.
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $7.78 to a high of $8.74. Yesterday, the shares gained 5.7%, which took the trading range above the 3-day high of...
How to Find Strong Cheap Stocks to Buy Under $10 Despite Coronavirus Fears
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March 10,...